P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

Introduction. In patients treated with ciltacabtagene autoleucel (cilta-cel), effective tumor burden reduction using bridging therapy correlates with better progression-free survival (PFS) and safety In CARTITUDE-4 (median follow-up, 33.6 months), a single cilta-cel infusion significantly improved...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	E. Zamagni, B. Dhakal, S. Iida, M.H. Sidiqi, S.S. Yoon, N. Callander, C. Touzeau, Q. Li, A. Balogh, A. Slaughter, N. Benachour, C. Lonardi, A. Ghosh, M. Vogel, N. Lendvai, T. Lengil, M. Koneru, N. Patel, O. Costa Filho, V. Mahajan, J. Martínez-López, K. Yong, K. Weisel, X. Leleu
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2026-04-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/14045
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!